REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2020

Dec 11, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2020-12-09

Reporting Person: STAHL NEIL (EVP Research and Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-26	Common Stock	G	750	$0.0	Disposed	20979	Direct
2020-12-09	Common Stock	A	1688	$0.0	Acquired	24715	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-09	Non-Qualified Stock Option (right to buy)	$492.0	A	17500	Acquired	2030-12-09	Common Stock (17500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5766	Indirect
Common Stock	9134	Indirect

Footnotes

F1: Award of Restricted Stock under the Second Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 9, 2022 and 50% on December 9, 2024.

F2: The stock option award vests in four equal annual installments, commencing one year after the date of grant.